34 related articles for article (PubMed ID: 9496389)
1. A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.
Bible KC; Peethambaram PP; Oberg AL; Maples W; Groteluschen DL; Boente M; Burton JK; Gomez Dahl LC; Tibodeau JD; Isham CR; Maguire JL; Shridhar V; Kukla AK; Voll KJ; Mauer MJ; Colevas AD; Wright J; Doyle LA; Erlichman C; ;
Gynecol Oncol; 2012 Oct; 127(1):55-62. PubMed ID: 22664059
[TBL] [Abstract][Full Text] [Related]
2. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR; Maibach R; Childs M; Rajput K; Roebuck D; Sullivan MJ; Laithier V; Ronghe M; Dall'Igna P; Hiyama E; Brichard B; Skeen J; Mateos ME; Capra M; Rangaswami AA; Ansari M; Rechnitzer C; Veal GJ; Covezzoli A; Brugières L; Perilongo G; Czauderna P; Morland B; Neuwelt EA
N Engl J Med; 2018 Jun; 378(25):2376-2385. PubMed ID: 29924955
[TBL] [Abstract][Full Text] [Related]
3. Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
Duinkerken CW; de Weger VA; Dreschler WA; van der Molen L; Pluim D; Rosing H; Nuijen B; Hauptmann M; Beijnen JH; Balm AJM; de Boer JP; Burgers JA; Marchetti S; Schellens JHM; Zuur CL
Otol Neurotol; 2021 Jun; 42(5):678-685. PubMed ID: 33710154
[TBL] [Abstract][Full Text] [Related]
4. Agile cycles: A strategy to complete courses during uncertain times.
Pereira PNR; Johnson M; Childs G; Ribeiro APD
J Dent Educ; 2020 Aug; ():. PubMed ID: 32844409
[No Abstract] [Full Text] [Related]
5. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer.
Bhatt A; Glehen O; Zivanovic O; Brennan D; Nadeau C; Van Driel W; Bakrin N
Ann Surg Oncol; 2023 Dec; 30(13):8115-8137. PubMed ID: 37561343
[TBL] [Abstract][Full Text] [Related]
6. Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study.
Kurreck A; Gronau F; Alberto Vilchez ME; Abels W; Enghard P; Brandl A; Francis R; Föhre B; Lojewski C; Pratschke J; Thuss-Patience P; Modest D; Rau B; Feldbrügge L
Ann Surg Oncol; 2022 Jan; 29(1):152-162. PubMed ID: 34350529
[TBL] [Abstract][Full Text] [Related]
7. Fully phosphorothioate-modified CpG ODN with PolyG motif inhibits the adhesion of B16 melanoma cells in vitro and tumorigenesis in vivo.
Wang X; Wang L; Wan M; Wu X; Yu Y; Wang L
Nucleic Acid Ther; 2013 Aug; 23(4):253-63. PubMed ID: 23848522
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin overdose: toxicities and management.
Tsang RY; Al-Fayea T; Au HJ
Drug Saf; 2009; 32(12):1109-22. PubMed ID: 19916578
[TBL] [Abstract][Full Text] [Related]
9. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.
Hoekman K; van der Vijgh WJ; Vermorken JB
Drugs; 1999 Feb; 57(2):133-55. PubMed ID: 10188757
[TBL] [Abstract][Full Text] [Related]
10. Combined carboplatin and cisplatin. Limited prospects for dose intensification.
Waterhouse DM; Reynolds RK; Natale RB
Cancer; 1993 Jun; 71(12):4060-6. PubMed ID: 8508371
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.
Howell SB; Kirmani S; McClay EF; Kim S; Braly P; Plaxe S
Semin Oncol; 1991 Feb; 18(1 Suppl 3):5-10. PubMed ID: 2003227
[TBL] [Abstract][Full Text] [Related]
12. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
van Rijswijk RE; Hoekman K; Burger CW; Verheijen RH; Vermorken JB
Ann Oncol; 1997 Dec; 8(12):1235-41. PubMed ID: 9496389
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group.
Guastalla JP; Vermorken JB; Wils JA; George M; Scotto V; Nooij M; ten Bokkel Huinnink WW; Dalesio O; Renard J
Eur J Cancer; 1994; 30A(1):45-9. PubMed ID: 8142163
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer.
de Jong RS; Willemse PH; Boonstra H; de Vries EG; van der Graaf WT; Sleijfer DT; van der Zee AG; Mulder NH
Eur J Cancer; 1995; 31A(5):709-13. PubMed ID: 7640042
[TBL] [Abstract][Full Text] [Related]
15. A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
Willemse PH; Sleijfer DT; de Vries EG; Boonstra H; Bouma J; Mulder NH
Eur J Cancer; 1992; 28(2-3):479-81. PubMed ID: 1591067
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
